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BACKGROUND:It was shown recently on the level of gene expression that UGT8, coding UDP-galactose:ceramide galactosyltransferase,
is one of six genes whose elevated expression correlated with a significantly increased the risk of lung metastases in breast cancer
patients. In this study primary tumours and their lung metastases as well as breast cancer cell lines were analysed for UGT8
expression at the protein level.
METHODS: Expression of UGT8 in breast cancer tissue specimens and breast cancer cell lines was analysed using IHC, real-time PCR
and Western blotting.
RESULTS: Comparison of the average values of the reaction intensities (IRS scale) showed a significant difference in UGT8 expression
between (1) primary and metastatic tumours (Mann–Whitney U, Po0.05), (2) tumours of malignancy grades G3 and G2
(Mann–Whitney U, Po0.01) as well as G3 and G1 (Mann–Whitney U, Po0.001) and (3) node-positive and node-negative tumours
(Mann–Whitney U, Po0.001). The predictive ability of increased expression of UGT8 was validated at the mRNA level in three
independent cohorts of breast cancer patients (721). Similarly, breast cancer cell lines with the ‘luminal epithelial-like’ phenotype did
not express or weakly expressed UGT8, in contrast to malignant, ‘mesenchymal-like,’ cells forming metastases in nude mice.
CONCLUSION: Our data suggest that UGT8 is a significant index of tumour aggressiveness and a potential marker for the prognostic
evaluation of lung metastases in breast cancer.
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The endoplasmic reticulum-localised enzyme UDP-galactose:ceramide
g a l a c t o s y l t r a n s f e r a s e( U G T 8 ,C G T ,C .E .2 . 4 . 2 . 6 2 )( S c h u l t ea n dS t o f f e l ,
1993; Kapitonov and Yu, 1997; Sprong et al, 1998) is responsible
for the synthesis of galactosylceramide (GalCer), which is the
major glycosphingolipid of myelin produced by oligodendrocytes
in the central nervous system (CNS) and Schwann cells in the
peripheral nervous system (Marcus and Popko, 2002). The exact
role of GalCer in myelin sheath development and function is
poorly understood; however this glycolipid is well recognised as a
specific marker for the differentiation of these cells (Pfeiffer et al,
1993). Studies using antibodies suggested that GalCer may
participate in signal transduction by regulating the intracellular
calcium level and in this way mediating cytoskeletal rearrange-
ments (Dyer and Benjamins, 1990, 1991). On the basis of a
knockout mice model lacking UGT8, it was proposed that GalCer,
together with sulphatide, is involved in myelin function and
stability but not in its biogenesis (Bosio et al, 1996; Coetzee et al,
1996; Dupree et al, 1999). In addition to myelin, GalCer was also
found in normal kidney (Ariga et al, 1980; Kodama et al, 1982),
small intestine and colon (Natomi et al, 1993), liver (Nilsson and
Svennerholm, 1982), testis (Vos et al, 1994), and milk (Bouhours
and Bouhours, 1979).
Since the pioneering work of Hakomori and Murakami (1968), it
was firmly established that neoplastic transformation and tumour
progression are almost invariably associated with changes in the
expression profiles of surface glycosphingolipids (Hakomori,
1996). However, there is very little information available on
GalCer expression in human tumours. Only in studies on
molecular markers in human astrocytomas and oligodendroglio-
mas was it found that high amounts of GalCer were present more
frequently in oligodendrogliomas than in astrocytomas (Sung et al,
1996; Popko et al, 2002). Interestingly, more is known about the
expression of UGT8 in cancerous tissues. Transcriptome profiling
of prostate cancer cell lines showed that cells with metastatic
properties express a much higher level of UGT8 mRNA in
comparison with non-metastatic cells (Oudes et al, 2005). Using
the same approach, we recently showed that UGT8 is one of six
genes whose elevated expression correlated with a significantly
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sincreased risk of lung metastases in breast cancer patients
(Landemaine et al, 2008). It was also found that elevated
expression of UGT8 in breast cancer was significantly associated
with ER-negativity, and therefore with a more malignant
phenotype (Yang et al, 2006; Ruckha ¨berle et al, 2008).
As all the available information on the presence of UGT8 in breast
cancer tissues was obtained only at the level of mRNA expression,
primary tumours of different malignancy grades and their lung
metastases were analysed for UGT8 expression at the protein level.
In addition, presence of UGT8 and GalCer was determined in breast
cancer cell lines representing different tumour phenotypes.
MATERIALS AND METHODS
Tissue specimens and cell lines
Tissue blocks from 10 patients with primary breast cancer
(invasive ductal carcinoma, IDC) were obtained from the
Department of Pathology, Lower Silesian Center of Oncology
(Wrocław, Poland) (eight cases) and Department of Pathology,
Centre Rene ´ Huguenin (Saint-Cloud, France) (two cases). Their
corresponding lung metastases were collected also as tissue blocks
from the Department of Thoracic Surgery, Wrocław Medical
University (Poland), and Department of Pathology, Centre Rene ´
Huguenin (Saint-Cloud, France) (Table 1). Thirty tissue specimens
were obtained from patients who underwent resections of primary
IDC at the Lower Silesian Center of Oncology, Wrocław (Poland)
(Table 1). For mRNA analysis they were frozen at  801C and for
immunohistochemical staining they were fixed in 10% neutral-
buffered formalin and embedded in paraffin. Paraffin sections,
mounted on Superfrost Plus slides (Menzel Glaser, Braunschweig,
Germany), were dehydrated and stained with haematoxylin and
eosin. Malignant tumours were graded according to the classifica-
tion of Bloom–Richardson with the modification of Elston and
Ellis (1991). The study was approved by the Bioethical Committee
of the Wrocław Medical University (no. KB-87/2005).
Three breast tumour series, the ‘MSK’, ‘EMS’, and ‘NKI’ cohorts
(van de Vijver et al, 2002; Wang et al, 2005; Minn et al, 2005a,b,
2007), for which microarray data are freely available, were also
included in this study.
The following breast cancer cell lines were used in this study:
MCF7, T47D, SKBR-3, BT-474, MDA-MB-231 (Cell Lines Collec-
tion of the Ludwik Hirszfeld Institute of Immunology and
Experimental Therapy, Wrocław, Poland), MCF10CA1a.cl1 (pro-
vided by Dr S Santner, Karmanos Cancer Institute, Detroit, USA)
and BO2 as a derivative of the MDA MB 231 cell line (provided by
Dr Philippe Clezardin, INSERM U664, France). The cells were
cultured in a-minimum essential medium (aMEM) supplemented
with 10% foetal calf serum (FCS; Invitrogen, Carlsbad, CA, USA),
2m ML -glutamine, and antibiotics.
Immunohistochemistry
For immunohistochemical staining, 4-mm-thick paraffin sections
were deparaffinised in xylene and gradually rehydrated using
ethanol. Endogenous peroxidase activity was blocked by a 5-min
exposure to 3% H2O2. The cultured cells in eight-well culture slides
(Becton Dickinson, Franklin Lakes, NJ, USA) were fixed in 4%
neutral-buffered formalin for 15min. Antigen retrieval was
performed by exposure of the tissue sections and breast cancer
cell lines to boiling Antigen Retrieval Solution (Dako, Glostrup,
Denmark) in a microwave oven (250W) for 15min. Rabbit
polyclonal antibodies directed against UGT8 were purchased from
Atlas Prestige Antibodies (Stockholm, Sweden). The antibodies
were diluted with Background Reducing Antibody Diluent (Dako).
The sections were incubated with primary antibodies for 1h at
room temperature. Goat secondary antibodies (EnVision/HRP;
Dako) directed against rabbit immunoglobulins were bound to a
dextran framework conjugated with peroxidase. The reaction was
developed using 3,30-diaminobenzidine tetrachloride (DAB).
Primary Negative Control (Dako) was used as the negative control.
All tissue sections were counterstained with Mayer’s haematoxylin.
The obtained photomicrographs were subjected to computer-
assisted image analysis using a computer coupled to an Olympus
BX-41 light microscope (Olympus, Tokyo, Japan) using the
AnalySis software (Olympus). The degree of UGT8 expression
was ranked using the modified semi-quantitative Immunoreactive
Remmele Score (IRS) according to Remmele and Stegner (1987).
The method takes into account both the proportion of stained cells
and the intensity of the reaction, while its final results represent
the product of the two parameters, with values ranging from 0 to
12 points (no reaction¼0 points, weak reaction¼1–2 points,
moderate reaction¼3–4 points, intense reaction¼6–12 points).
The results were subjected to statistical analysis using the
Statisitica 7.1 software (StatSoft, Krako ´w, Poland). When groups
of data were compared, which failed to satisfy assumptions of the
parametric test, the Mann–Whitney U-test, the non-parametric
equivalent of Student’s t-test, was used. For matched samples of
primary tumours and their metastases, the Wilcoxon signed rank
sum test, the non-parametric version of a paired-samples t-test,
was used. Correlations were tested by Spearman’s correlation
analysis. Results were considered statistically significant with
Po0.05 in all analyses. Survivals times were determined by the
Kaplan–Meier method and significance of differences were
determined by log-rank test.
RT-PCR and real-time PCR
Total RNA was isolated from the tissue samples using the RNeasy
Fibrous Tissue Mini Kit (Qiagen, Hilden, Germany) according to
Table 1 Patients and tumour characteristics
Tumours without
lung metastases
Tumours with
lung metastases
Mean age in years (range) 58.4 (32–80) 59.8 (43–71)
Parameters Number % Number %
Invasive ductal carcinoma (IDC) 30 100.0 10 100.0
Size
T1 (o2cm) 16 53.3 3 30.0
T2 (2–5cm) 11 36.7 4 40.0
T3 (45cm) 3 10.0 3 30.0
Lymph nodes
Negative 22 73.3
Positive 8 26.7 10 100.0
Grade
G1 8 26.7 1 10.0
G2 7 23.3 3 30.0
G3 15 50.0 6 60.0
ER
Positive 20 66.7 4 40.0
Negative 10 33.3 6 60.0
PR
Positive 13 43.3 7 70.0
Negative 17 56.7 3 30.0
HER2 by IHC
Positive 6 20.0 2 20.0
Negative 24 80.0 8 80.0
Abbreviations: ER¼estrogen receptor; IHC¼immunohistochemistry; PR¼
progesterone receptor.
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sthe manufacturer’s instructions. The protocol included on-column
DNAse digestion to remove the genomic DNA. First-strand cDNA
was synthesised using the SuperScript III First-Strand Synthesis
System (Invitrogen, Carlsbad, CA, USA). The relative amounts of
UGT8 mRNA were determined by quantitative real-time PCR with
an iQ5 Optical System and iQ SYBR Green Supermix (Bio-Rad,
Hercules, CA, USA) according to the manufacturer’s protocols.
GAPDH was used as a reference gene. The primers used were:
realUGT8f/realUGT8r for UGT8 and SGAPDH/ASGAPDH for
GAPDH (Table 2). The reactions were performed under the
following conditions: initial denaturation at 941C for 120s,
followed by 35 cycles of denaturation at 941C for 30s, annealing
at 581C for 30s, and elongation at 721C for 60s. The specificity of
the PCR was determined by melt-curve analysis for each reaction.
SDS-PAGE and Western blotting
Cell lysates were obtained by treating the cells with RIPA lysis buffer
(50mM Tris-HCl, pH 8.0, 150mM NaCl, 0.1% SDS, 1% IGEPAL Ca-
630, 0.5% sodium deoxycholate). Proteins were quantified using a
bicinchonic acid protein assay kit (Sigma-Aldrich, St Louis, MO,
USA) and subjected to electrophoresis on 8% SDS-PAGE gel
according to Laemmli. After electrophoresis, the proteins were
transferred to a nitrocellulose membrane (Bio-Rad). UGT8 was
detected with rabbit polyclonal antibodies (Atlas Antibodies,
Stockholm, Sweden) and horseradish peroxidase-conjugated
donkey anti-rabbit immunoglobulins (Jackson Immuno-
Research, West Grove, PA, USA). The bound antibodies were
visualised with the Lumi-Light
PLUS Luminal/Enhancer Solution and
Lumi-Light
PLUS Stable Peroxidase Solution (Roche, Basel, Switzer-
land). The light-sensitive membrane was then developed by
incubating with the Kodak Developer and Kodak Fixer according
to the kit’s protocol (Kodak, Rochester, NY, USA).
Purification of neutral glycolipids and thin-layer
chromatogram binding assay
Neutral glycolipids were purified as described previously (Ugorski
et al, 1989). Cell pellets corresponding to 10
8–10
9 cells were
extracted with chloroform/methanol/water, 20/10/1, 10/20/1, and
10/10/1 by volume. Combined extracts were subjected to mild
alkaline hydrolysis with 0.2M KOH in methanol and desalted on a
column of Sephadex G-25 superfine (Pharmacia Biotech, Uppsala,
Sweden). The gangliosides were separated from the neutral
glycolipids on a DEAE-Sephadex A-25 column (Pharmacia
Biotech). The neutral glycolipids were further purified after
acetylation on a Florisil column (Merck, Darmstadt, Germany)
and analysed by high-performance thin-layer chromatography
(HP-TLC) on silica gel 60 HP-TLC plates (Merck) with a solvent
system of 2-propanol/15M ammonia solution/methyl acetate/
water, 75/10/5/15 by volume. (Ogawa et al, 1988). The standard
for GalCer was obtained from Sigma-Aldrich. GalCer was detected
by a TLC binding assay with rabbit polyclonal antibodies directed
against GalCer (Sigma-Aldrich) and AffiniPure goat anti-rabbit
IgG (Jackson ImmunoResearch) (Magnani et al, 1982). The latter
were labelled with K
125I (PerkinElmer, Waltham, MA, USA) using
Iodo-Beads Iodination Reagent (Pierce, Rockford, IL, USA)
according to the manufacturer’s instructions.
RESULTS
Expression of UGT8 in primary breast cancer tumours
and their metastases to the lung
On the basis of histological examination 10 primary breast
carcinomas and their matched metastases were included in this
study. The primary carcinomas were classified according to the
Bloom–Richardson scale in the modification of Elston and Ellis
(1991) as G1 (1 case), G2 (3 cases), and G3 (6 cases). Expression of
UGT8 in the paraffin sections of the cancer tissue specimens was
analysed using rabbit polyclonal antibodies. All primary tumours
except one stained more weakly with anti-UGT8 antibodies than
did the lung metastases (Figure 1). Comparison of the average
values of the reaction intensities (IRS scale) showed a significant
difference (Wilcoxon t-test, Po0.017) in UGT8 expression between
primary and metastatic tumours (Table 3). Using IHC, UGT8
expression was also studied in the primary tumours according to
their malignancy grades. For staining with anti-UGT8 antibodies,
additional paraffin sections from 8 tumours of grade G1, seven
tumours of grade G2, and 15 tumours of grade G3 were included.
Table 2 Oligonucleotide primers used in real-time PCR experiments
Target
sequence Name
Primer
location
in human
cDNA
Nucleotide sequence
of primers (50-30)
Product
size (bp)
UGT8 RealUGT8f 834-854 ATGGGTAAATGGTGCTAATG 334
RealUGT8r 1145’1167 TCTGGTCATAGTATCATAATGG
GAPDH SGAPDH 536-553 TCACTGCCACCCAGAAGA 399
ASGAPDH 916’935 TACCAGGAAATGAGCTTGAC
200 m
200 m
Figure 1 Immunohistochemical staining of primary breast carcinoma (A)
and paired lung metastasis (B) with anti-UGT8 rabbit polyclonal antibodies.
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sIt was found that the expression of UGT8 in the tumour cells
increased with increasing malignancy grade, reaching the highest
values in the weakly differentiated cells (G3) (Figure 2A–C). When
the average values of the reaction intensities (IRS scale) for
tumours of different histological differentiation were compared by
the Mann–Whitney U-test significant differences in UGT8
expression between malignancy grades G3 and G2 (Po0.01) as
well as G3 and G1 (Po0.001) were found (Figure 2D). The results
obtained at the protein level were confirmed when 30 primary
tumours available as tissue specimens were also analysed by real-
time PCR (Figure 3A). A significant positive correlation (r¼0.58,
Po0.05) between the expression of UGT8 protein and UGT8
mRNA was found using Spearman’s correlation analysis
(Figure 3B). The intensity of UGT8 staining in node-positive
breast cancer tumours, according to the IRS scale, amounted on
average to 4.7±1.53 and in node-negative tumours to 2.41±1.24
This difference also proved to be significant (Po0.001) (Figure 4).
To validate the predictive ability of the elevated expression of
UGT8 in primary breast tumours, the level of mRNA for UGT8 was
analysed in three independent cohorts of breast cancer patients
whose microarray data were available (van de Vijver et al, 2002;
Wang et al, 2005; Minn et al, 2005a,b, 2007) (Figure 5). In all three
analysed cohorts, patients assigned to the high-risk group had
significantly shorter lung metastasis-free survival.
Expression of UGT8 in established breast cancer cell lines
The following breast cancer cell lines were used to analyse the
expression of UGT8 with rabbit polyclonal antibodies: MCF-7,
Table 3 Immunohistochemical expression of UGT8 in primary breast
carcinomas and paired lung carcinomas
a
IRS scale
a
Number Primary tumour Lung metastasis
12 4
23 2
31 3
42 3
51 1
61 2
72 4
82 4
92 3
10 2 4
Mean 1.8 3.0
S.d. 0.63 1.05
P 0.017
Abbreviation: IRS¼Immunoreactive Remmele Score.
aReaction intensities with
rabbit polyclonal antibodies for UGT8 were calculated on the basis of the
semi-quantitative IRS scale of Remmele and Stegner (1987) and are represented
as means. Po0.017 for UGT8-expressing primary breast tumours as compared with
that for matched lung metastases (Wilcoxon signed rank sum test).
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Figure 2 Immunohistochemical staining of primary breast carcinomas
representing different malignancy grades (G1–G3). UGT8 expression in
primary breast carcinomas of different malignancy grades: (A)G 1( n¼9),
(B)G 2( n¼10), and (C)G 3( n¼21). Reaction intensities with rabbit
polyclonal antibodies for UGT8 (D) were calculated on the basis of the
semi-quantitative IRS scale of Remmele and Stegner (1987) and are
represented as means; *Po0.01 for primary breast tumours of grade G3 as
compared with primary breast tumour of grade G2, and
#Po0.001 for
primary breast tumours of grade G3 as compared with primary breast
tumours of grade G1 (Mann–Whitney U-test).
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Western blot analysis showed that high UGT8 expression was
limited to the metastasising MCF10CA1a.cl1, MDA-MB-231, and
BO2 cells (Figure 6A), and no binding was observed for the rest of
the analysed cells. These results were confirmed by real-time PCR
(Figure 6B) and immunohistochemical staining with anti-UGT8
polyclonal antibodies (data not shown).
Detection of GalCer in established breast cancer cell lines
Neutral glycolipids purified from the breast cancer cell lines were
separated on HP-TLC plates and immunostained with rabbit polyclonal
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Figure 5 Validation of UGT8 expression as a predictive marker of lung
metastasis in three independent series of breast cancer patients. Lung
metastasis-free survival was analysed for (A) MSK (n¼82), (B) NKI
(n¼295), and (C) EMC (n¼344). Kaplan–Meier analysis distinguished
patients who expressed high levels (high-risk group) and low levels (low-
risk group) of UGT8. Patients with high expression of UGT8 had a shorter
lung metastasis-free survival.
R
e
l
a
t
i
v
e
 
e
x
p
r
e
s
s
i
o
n
 
l
e
v
e
l
s
 
(
d
d
C
T
)
U
G
T
8
 
(
I
H
C
)
UGT8 (mRNA real-time PCR)
0 1000 2000 3000 4000 5000 6000 –1000
9
8
7
6
5
4
3
2
1
0
–1
6000
5000
4000
3000
2000
1000
0
G1 G2 G3
Figure 3 (A) Expression of UGT8 mRNA in primary breast tumours of
different malignancy grades. Real-time RT-PCR was used to analyse UGT8
mRNA. UGT8 levels were normalised against GAPDH and cell line MCF-7
was assigned as a calibrator sample. (B) Positive correlation between
intensity of UGT8 expression (immunohistochemistry, IHC) and UGT8
mRNA level (real-time PCR) in invasive ductal carcinoma. r¼0.58, Po0.05
(Spearman’s correlation).
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Figure 4 UGT8 expression (A) in node-negative invasive ductal
carcinomas (n¼22) and (B) node-positive invasive ductal carcinomas
(n¼18). Po0.05 for UGT8-expressing, node-negative primary breast
tumours as compared with node-positive primary tumours (Mann–
Whitney U-test). Reaction intensities with rabbit polyclonal antibodies for
UGT8 were calculated on the basis of the semi-quantitative IRS scale of
Remmele and Stegner (1987) and are represented as means.
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as bands of appropriate mobility, was seen only in neutral glycolipid
fractions isolated from metastasising breast cancer MCF10CA1a.cl1,
MDA-MB-231, and BO2 cells (Figure 7). No bands were detected
when using neutral glycolipids isolated from the rest of the analysed
cell lines (BT474, SKBR-3, T47D, and MCF-7).
DISCUSSION
Breast carcinoma is the leading cause of mortality due to
malignancy in Europe and North America. Death from breast
cancer is mainly due to distant metastases, which are organ-
specific and localise to bones, liver, lung, and brain (Fidler, 2003).
On the basis of transcriptome analysis of primary tumours and
distant metastases using genome-wide microarray techniques, it
was proposed that the risk for developing metastases can be
predicted by a ‘metastatic-gene signature’ expressed by subsets of
primary tumours (van’t Veer et al, 2002; Ramaswamy et al, 2003;
Weigelt et al, 2003; Driouch et al, 2007). With the use of a nude
mice model it was further shown that clones of MDA-MB-231
breast cancer cells developing organ-specific metastases in bone or
lung are characterised by the expression of specific subsets of non-
overlapping genes (Kang et al, 2003; Minn et al, 2005a,b). This
finding suggested the existence of specific gene signatures
determining the localisation of metastases in specific organs,
which was confirmed in three independent series of breast
tumours showing that the ‘lung metastasis signature’ is predictive
of high risk for the development of lung metastases (Minn et al,
2005a,b, 2007). Recently, a six-gene signature predicting breast
cancer lung metastases obtained for metastatic human tissue
specimens was published (Landemaine et al, 2008), which
correlated with increased risk of lung metastasis in a series of 72
lymph node-negative breast tumours. These data were further
validated on a larger series of samples (Driouch et al, 2009).
Among six genes highly overexpressed in lung metastases as
compared with that in other breast cancer metastases, UGT8,
which encodes an enzyme responsible for the synthesis of
galactosylceramide, was found (Landemaine et al, 2008). In other
studies on breast cancer, it was shown that elevated expression of
UGT8 was significantly associated with ER-negativity and therefore
with a more malignant phenotype (Yang et al, 2006; Ruckha ¨berle
et al, 2008). These studies indicating an elevated level of UGT8 in
more malignant breast cancer cells were performed only at the
level of mRNA expression using microarray analysis and
quantitative RT-PCR. In our study we evaluated UGT8 protein
expression in primary breast cancer tumours and their matched
lung metastases using IHC. Significantly stronger staining with
rabbit polyclonal antibodies directed against UGT8 was observed
in the specimens from lung metastases than in paired primary
tumours, confirming earlier results obtained at the mRNA level.
These data suggested that UGT8 is associated in some way with
tumour progression, and that its elevated level could be important
in the development of lung metastases (see below). Therefore, to
study the changes in UGT8 expression during increasing
malignancy of breast cancer cells in more detail, samples of breast
tumours having different malignancy grades were analysed for the
presence of UGT8 at the protein as well as mRNA level. It was
found that the amounts of UGT8 protein and mRNA increased
with tumour malignancy grades, and highly significant differences
in UGT8 expression were found in G3 tumours vs G2 tumours.
Interestingly, highly increased expression of UGT8 was also
observed in primary node-positive tumours as compared with
that in node-negative primary tumours. When the predictive value
of UGT8 expression was further analysed at the mRNA level in
primary tumours of the 721 breast cancer patients of the three
independent cohorts, the patients assigned to the high-risk group
had significantly shorter lung metastasis-free survival. Therefore,
our data suggest that UGT8 is a significant index of tumour
aggressiveness and potential marker for the prognostic evaluation
of lung metastases in breast cancer.
According to Lacroix and Leclercq (2004) breast cancer cell lines
can be classified into three groups on the basis of their phenotype
and invasiveness. The first group, including BT-483, MCF-7,
T-47D, and ZR-75 cells, was named ‘luminal epithelial-like’
because the cells highly express such genes as ER, CDH1
(E-cadherin), TJP1 (zonula occludens-1), and DSP (desmoplakin-
I/II), typical of the epithelial phenotype of breast cells. All these
cells are weakly invasive. The second group, called ‘weakly luminal
epithelial-like’, represented by SKBR-3 cells and BT-474, is similar
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Figure 6 (A) Western blot analysis of anti-UGT8 rabbit polyclonal
antibodies binding to cellular proteins of breast cancer cell lines. Cell lysates,
equivalent to 15mg of protein, were separated by SDS-PAGE under reducing
conditions on an 8% gel and electrophoretically transferred onto a nitrocellulose
membrane. b-Actin served as an internal control. (B) Expression of UGT8
mRNA in breast cancer cell lines. Real-time RT-PCR was used to analyse UGT8
mRNA. UGT8 levels were normalised against GAPDH and cell line MCF-7 was
assigned as a calibrator sample. Results are expressed as means.
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Figure 7 Immunostaining of neutral glycolipids from human breast
cancer cell lines, separated by HP-TLC, with anti-GalCer rabbit polyclonal
antibodies. For the analysed cell lines, an aliquot of total neutral glycolipids
corresponding to 1 10
7 cells was applied to the HP-TLC plate.
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sto the first group, expressing the same epithelial markers, although
at lower levels. The cells belonging to the third group are quite
different as they express proteins found in mesenchymal cells, for
example vimentin, and are highly invasive in vitro. They were
named ‘mesenchymal-like’ (‘stromal-like’) and are represented by
MDA-MB-231 and MCF10CA1a.cl1 cells. As the first two groups
probably correspond to tumours of grades G1 and G2, and the
‘mesenchymal-like’ group could represent G3 tumours, we
analysed the expression of UGT8 in different breast cancer cell
lines. Expression of UGT8 at the mRNA and protein level in the
established breast cancer cell lines correlated well with the results
obtained for the clinical samples. Cells with the ‘luminal epithelial-
like’ phenotype (MCF-7, T47D, SKBR-3, and BT-474) did not
express or weakly expressed UGT8, in contrast to the malignant,
‘mesenchymal-like’ cells (MCF10CA1a.cl1, MDA-MB-231, and
BO2) forming metastases in the nude mice model.
UGT8 is responsible for the synthesis of galactosylceramide,
which is the major glycosphingolipid of myelin in the CNS and
peripheral nervous system (Marcus and Popko, 2002). There is
very little information available on GalCer expression in human
tumours, except for human astrocytomas and oligodendrogliomas
(Sung et al, 1996; Popko et al, 2002). Very little is also known
about the possible functions of GalCer in tumour cells, which is in
striking contrast to glucosylceramide (GlcCer), the other simple
glycosphingolipid consisting only of ceramide and glucose residue.
It is widely accepted that GlcCer is a mitogenic molecule, as
stimulation of its synthesis decreases the intracellular pool of
ceramide, which has an important function in programmed cell
death as a proapoptotic agent (Radin, 2001; Taha et al, 2006).
Interestingly, several lines of evidence suggest that overexpression
of glucosylceramide synthase and accumulation of GlcCer can lead
to the development of drug resistance in cancer cells (Lavie et al,
1996; Okazaki et al, 1998; Radin, 2001). Therefore we analysed the
presence of GalCer in breast cancer cells and found that the
‘mesenchymal-like’ cells MDA-MB-231, BO2, and MCF10CA1a.cl1,
each forming metastases in nude mice, are the only cell lines
synthesising this glycolipid. This finding is in agreement with the
hypothesis of Beier and Gorogh (2005), who proposed that
accumulation of GalCer in tumour cells inhibits apoptosis, which
facilitates metastatic cells to survive in the hostile microenviron-
ment of the target organ. However, further functional studies are
necessary to confirm this hypothesis.
In summary, we have shown for the first time that (1) expression
of UGT8 is higher in breast cancer metastases to the lung than in
matched primary tumours and that increased amounts of this
enzyme in cancerous tissue are associated with progression to a
more malignant phenotype, and (2) expression of UGT8 and
GalCer is limited only to breast cancer cell lines forming
metastases in a nude mice model.
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